Few countries outside the U.S. have a comprehensive plan to fight resistance, monitoring is infrequent and sales of medicines without a prescription are rampant, according to a 2015 World Health Organization survey. So while regulators and consumers seek to reduce use in the U.S., developing nations serve as a willing market.
Maybe the hit to such companies as ZTS from the FDA’s new regulations (effective Jan 2017) will be as small as the companies say:
“We don’t think that this will represent a negative impact to our business,” said [LLY’s animal-health president, Jeff Simmons].
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”